Fig. 1From: Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicityKaplan-Meier survival plots illustrating a) percentage (%) freedom-from-local-progression (FFLP) in months and b) percentage (%) overall survival (OS) in monthsBack to article page